Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziv-aflibercept versus ranibizumab for macular edema secondary to central retinal vein occlusion
PACTR202609559057862Completed
- Sponsor
- Ahmed Abdelrahman Mohamed Mohamed Saber
- Start
- Oct 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of aflibercept and ranibizumab in central retinal vein occlusion (CRVO) (2 arms), sponsored by Ahmed Abdelrahman Mohamed Mohamed Saber. Started Oct 2024; status: completed.
02
Drugs
afliberceptranibizumab
03
Conditions
central retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on PACTR202609559057862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202609559057862.